Trial: 201912015

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin
Expression Who Have Failed Standard Available Therapy

Phase

I/II

Principal Investigator

Opyrchal, Mateusz

Disease Site

Other Female Genital; Other Respiratory and Intrathoracic Organs; Ovary; Pancreas; Soft Tissue

Learn more about this study at: clinicaltrials.gov